To determine whether prophylactic pancreatic duct stenting reduces pancreatic fistula (PF) formation after distal pancreatectomy (DP).
PF causes major morbidity after DP. Transpapillary pancreatic stenting has been proposed to be beneficial in treating established PF and also, prophylactically, to reduce the risk for PF after DP.
Patients scheduled for DP during October 2006 to December 2010 were assessed and, if eligible, randomized to DP without (DP) or with stenting before transection of the neck of the gland (DP + stent). DP procedure was standardized and the follow-up period included the first 30 postoperative days. The outcomes were assessed according to the intention to treat analysis principle.
Sixty-four patients were assessed and 58 were randomized to either DP (n = 29) or DP + stent (n = 29). Mean ± SD operation time for DP was 218.8 ± 94.1 compared to 283.3 ± 131.9 for DP + stent (P = 0.052). Clinically significant PF (ISGPF [The International Study Group on Pancreatic Fistula] classification Grade B or C) occurred in 6 DP (22.2%) and 11 (42.3%) DP + stent patients (odds ratio: 2.57, 95% confidence interval 0.78–8.48; P = 0.122). The mean hospital stay for patients without stent was 13.4 ± 6.4 days compared to 19.4 ± 14.4 days for those provided with a pancreatic stent (P = 0.071).
The results from this trial show that prophylactic pancreatic stenting does not reduce PF when performing a standardized resection of the body and tail of the pancreas. The trial was registered at clinicaltrials.gov NCT00500968.
The objective of this study was to determine, with the help of a randomized controlled trial, whether prophylactic pancreatic duct stenting reduces pancreatic fistula formation after distal pancreatectomy.
*Department of Clinical Science and Education, Karolinska Institutet, Department of Surgery, Södersjukhuset, Stockholm, Sweden
†Department of Surgical Gastroentrology, Karolinska University Hospital, Stockholm, Sweden.
Reprints: Farshad Frozanpor, MD, PhD, Department of Surgery, Södersjukhuset, Sjukhusbacken 10, 118 83 Stockholm, Sweden. E-mail: email@example.com.
Disclosure: The trial was not sponsored or supported by any organization or grants. Authors have no commercial associations that might pose a conflict of interest.